World's tallest trees on fire in Oregon
A main challenge in tackling the fire is where it is located within the tree. While firefighters have managed to stop the fire on tree's canopy - its branches and leaves - there is a fire still burning inside the trunk. An infrared drone flight showed that one area of heat is about 280 feet up the trunk.This is where a fire is burning - inside the trunk itself.
Sprinklers have been placed at the bottom of the trunk, while helicopter teams were able to drop water from buckets on the leaf canopy above. But due to safety concerns fire managers have said climbing crews will not be used. Debris from the treetop has also made it unsafe for crews to work directly under the tree with the risk of falling parts of the treetop making it dangerous for crews to work directly under the treeDoerner Fir is one of the largest coastal Douglas Fir trees in the world, and is estimated to be between 450 and 500 years old. It is one of the largest non-redwood trees.How the tree caught fire is still a mystery.Investigators from the Bureau of Land Management are working find out the cause, but have ruled out lightening after looking at weather data.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Solar may account for half of new US electricity added this year, EIA says
NEW YORK, Aug 20 (Reuters) - Developers are on track to add 33 gigawatts of solar power in the U.S. this year, accounting for about half of the total new electricity generating capacity planned for the country in 2025, the Energy Information Administration said on Wednesday. If the plans are realized, large-scale solar power additions in the U.S. would reach a record high, said the EIA, which based its analysis on a survey of developers. New battery storage, which stores electricity from solar farms and other energy sources, may also hit a yearly record in 2025. Wind and natural gas power plants accounted for the rest of the capacity additions, the EIA said. Solar energy does not produce global warming emissions. That makes it central to plans by U.S. states to decarbonize, while also meeting record-high electricity demand brought on by Big Tech and other expanding industries. Many of the federal government financial incentives that propelled the development of solar power over the last several years, however, will disappear under the administration of President Donald Trump, adding uncertainty to future development of the technology. Texas, which last year surpassed California as the state with the most large-scale solar capacity, accounted for more than a quarter of the solar power developed so far in 2025. For the rest of the year, the Lone Star State plans for another 9.7 gigawatts of new solar capacity, or nearly half of all of U.S. solar planned for development over the time period. Texas' sunny weather, availability of large amounts of land and quickly-increasing power demand have drawn solar energy development.
The Independent
5 hours ago
- The Independent
Women who give birth before 21 are at higher risk of these conditions
Women who give birth before the age of 21 are twice as likely to suffer from type 2 diabetes, heart failure, and obesity, a new study has found. It also reveals they are four times more likely to develop severe disorders that affect the metabolism. Researchers from The Buck Institute for Research on Ageing said that girls who go through puberty before the age of 11 will face the same risks. they receive outside of [obstetrics and gynaecology]. 'These risk factors, whether positive or negative, clearly have a significant influence on a variety of age-related diseases and should be considered in the larger context of overall health.' The research also shows that later childbirth and puberty are genetically tied to longer lifespans and a reduced risk of age-related diseases such as type 2 diabetes and Alzheimer's. The study analysed nearly 200,000 women who participated in the research hub UK Biobank and identified 126 genetic markers that reveal the effects of early puberty and childbirth on ageing. Dr Kapahi said the public health implications of the research were significant. He said: 'We show that genetic factors favouring early reproduction come with significant cost later in life, including accelerated ageing and disease. It makes sense that the very factors that help enhance survival of the offspring may lead to detrimental consequences for the mother.' The role of Body Mass Index (BMI) is a critical cause of the effects, he said. Early reproduction contributes to a higher BMI, which makes you more prone to health problems. 'One can envisage that enhancing the ability to absorb nutrients would benefit the offspring, but if nutrients are plentiful, then it can enhance the risk of obesity and diabetes,' Dr Kapahi added. He is now asking how this knowledge can be used to improve female health: 'If evolution has shaped us to prioritise early reproduction at the cost of ageing, how can we leverage this knowledge to extend healthspan in modern society? "While we cannot change our genetic inheritance, understanding these genetic tradeoffs empowers us to make informed choices about health, lifestyle and medical care."
Reuters
5 hours ago
- Reuters
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
Aug 20 (Reuters) - The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' (RCKT.O), opens new tab gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares soared over 30% in morning trading on Wednesday. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
